Therakind enters exclusive distribution partnership with Pharmalink
Jylamvo targets United Arab Emirates market
09 January 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with Pharmalink for Therakind’s lead product, Jylamvo. The partnership also announces today the successful launch of Jylamvo in the UAE.
Under this agreement, Pharmalink secures exclusive rights to market, commercialise and sell Jylamvo in the United Arab Emirates (“UAE”). Jylamvo is already on sale in UK, Greece, Poland and Romania.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“The building of our distribution network is going from strength to strength as we now add Pharmalink to the Therakind family for access to the UAE. For our patients, this means access to medicines designed specifically to meet their needs. Jylamvo is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. With access in Europe, the UK and the Middle East, our products are gaining a reputation for being safe and effective across the age groups, including children.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
